Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ravi Retnakaran MD, FRCPC, FCAHS

Ravi Retnakaran MD, FRCPC, FCAHS

Professor of Medicine, Division of Endocrinology, University of Toronto; Clinician-Scientist, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada

Dr. Ravi Retnakaran is a Professor of Medicine at the University of Toronto and an endocrinologist and clinician-scientist at Mount Sinai Hospital in Toronto, Canada, where he holds the Boehringer Ingelheim Chair in Beta-cell Preservation, Function and Regeneration. He was awarded the 2013 Dr. Charles Hollenberg Young Investigator Award by the Canadian Society of Endocrinology and Metabolism and the 2014 Joe Doupe Award from the Canadian Society of Clinical Investigation. In 2020, he was named to the Canadian Academy of Health Sciences. His research program focuses on the pathophysiology and treatment of type 2 diabetes (T2DM), with a particular interest in the potential reversibility of pancreatic beta-cell dysfunction early in the course of diabetes. In this context, his research group is conducting a series of innovative clinical trials evaluating novel therapeutic strategies for the preservation of beta-cell function in early T2DM. In addition, his research program has advanced the concept that a women’s gluco-regulatory response to the metabolic challenge posed by pregnancy can provide unique insight into her future risk of T2DM and cardiovascular disease.


Dr. Retnakaran receives grants from Boehringer Ingelheim and Novo Nordisk and does consulting for Novo Nordisk, Sanofi, and Eli Lilly. None of these activities relate to the topic of his commentary.